CTI BioPharma Corp. (CTIC) Receives Daily News Impact Rating of 0.25
Media coverage about CTI BioPharma Corp. (NASDAQ:CTIC) has been trending positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CTI BioPharma Corp. earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 47.9282093508719 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media headlines that may have impacted Accern’s rankings:
- CTI BIOPHARMA CORP : Regulation FD Disclosure (form 8-K) (4-traders.com)
- ETFs with exposure to CTI BioPharma Corp. : November 10, 2017 (finance.yahoo.com)
- CTI BioPharma to Present at the Jefferies 2017 London Healthcare Conference – PR Newswire (press release) (prnewswire.com)
- FY2017 Earnings Forecast for CTI BioPharma Corp. Issued By Jefferies Group (CTIC) (americanbankingnews.com)
- CTI BioPharma’s (CTIC) CEO Adam Craig on Q3 2017 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
Several equities analysts have commented on the stock. Jefferies Group LLC assumed coverage on shares of CTI BioPharma Corp. in a report on Tuesday, September 12th. They issued a “buy” rating and a $7.50 target price on the stock. ValuEngine lowered shares of CTI BioPharma Corp. from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 11th.
CTI BioPharma Corp. (CTIC) opened at $2.86 on Tuesday. The company has a quick ratio of 2.17, a current ratio of 2.19 and a debt-to-equity ratio of 0.26. CTI BioPharma Corp. has a 1-year low of $2.70 and a 1-year high of $6.48.
CTI BioPharma Corp. (NASDAQ:CTIC) last posted its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. CTI BioPharma Corp. had a negative net margin of 96.91% and a negative return on equity of 209.67%. The company had revenue of $1.71 million for the quarter, compared to the consensus estimate of $0.30 million. research analysts expect that CTI BioPharma Corp. will post -1.2 EPS for the current year.
In other news, Director Richard L. Love sold 14,600 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $3.21, for a total value of $46,866.00. Following the sale, the director now directly owns 84,318 shares in the company, valued at approximately $270,660.78. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 8.08% of the company’s stock.
WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/cti-biopharma-corp-ctic-receives-daily-news-impact-rating-of-0-25/1701635.html.
CTI BioPharma Corp. Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.